We are committed to serving the best interests of our shareholders. The investor pages that follow are your resource for financial information about Catalyst Biosciences, Inc.
NASDAQ: CBIO$4.750.02 (0.42%)Oct 17, 20173:59 p.m. ET
Delayed at least 15 minutes
Data provided by Nasdaq. Minimum 15 minutes delayed.
Press ReleasesSeptember 26, 2017Catalyst Biosciences Granted FDA Orphan Drug Designation for Subcutaneous Recombinant Human Factor IX Variant for Treatment of Hemophilia BSeptember 25, 2017Catalyst Biosciences Announces Successful Completion of First Subcutaneous Dosing Cohort in Ongoing Hemophilia B Clinical TrialSeptember 22, 2017Catalyst Biosciences to Present at the Ladenburg Thalmann 2017 Healthcare ConferenceView all press releases »
Reverse Stock Split
|For the 1 for 15 Reverse Stock Split Tax Form, click here|
Targacept Special Dividend
|For the FAQ and additional information, click here.|
Catalyst Biosciences, Inc.
Red House Consulting, LLC